Patents Assigned to Tiltan Pharma Ltd.
  • SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES
    Publication number: 20110071100
    Abstract: The subject of the invention provides a pharmaceutical composition comprising a sulfobetaine, a sulfobetaine for therapy, uses thereof and methods of treating cancer obesity, age related macular degeneration or neurodegenerative diseases comprising administering a composition comprising a sulfobetaine.
    Type: Application
    Filed: May 5, 2009
    Publication date: March 24, 2011
    Applicant: TILTAN PHARMA LTD.
    Inventors: Shmuel A. Ben-Sasson, Arie Dagan
  • Anti-cancer therapy comprising an H2-blocker, at least one antiinflammatory agent and a cytotoxic agent
    Patent number: 7838513
    Abstract: The present invention relates to the treatment of a mammal with a pharmaceutical composition comprising an H2-blocker, at least one anti-inflammatory agent, a cytotoxic agent and, optionally, levamisole, a retinoid, an NFkB inhibitor, a redox quinone, an agent that enhances the intracellular accumulation of NADH+H+, a poly-alcohol, an inhibitor of pro-angiogenic growth factor(s) and an MMP inhibitor, such pharmaceutical composition allowing for the enhanced therapy and/or prevention of neoplastic diseases and disorders.
    Type: Grant
    Filed: July 4, 2007
    Date of Patent: November 23, 2010
    Assignee: Tiltan Pharma Ltd.
    Inventor: Shmuel A. Ben-Sasson
  • ANTI-CANCER THERAPY COMPRISING AN H2-BLOCKER, AT LEAST ONE ANTIINFLAMMATORY AGENT AND A CYTOTOXIC AGENT
    Publication number: 20090318391
    Abstract: The present invention relates to the treatment of a mammal with a pharmaceutical composition comprising an H2-blocker, at least one anti-inflammatory agent, a cytotoxic agent and, optionally, levamisole, a retinoid, an NFkB inhibitor, a redox quinone, an agent that enhances the intracellular accumulation of NADH+H+, a poly-alcohol, an inhibitor of pro-angiogenic growth factor(s) and an MMP inhibitor, such pharmaceutical composition allowing for the enhanced therapy and/or prevention of neoplastic diseases and disorders.
    Type: Application
    Filed: July 4, 2007
    Publication date: December 24, 2009
    Applicant: TILTAN PHARMA LTD.
    Inventor: Shmuel A. Ben-Sasson